Clinical Trial Update: Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers [Phase 2]

View source ↗

Summary

A Phase 2 trial tested topiramate to reduce heavy drinking in HIV-positive individuals; the study was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• HIV Infection

Drugs mentioned

• Topamax (Topiramate)

Snippet

Sponsor: University of Pennsylvania | Conditions: Heavy Drinking, HIV | Phase 2 | Status: TERMINATED | Results posted: 2016-02-17